NRC · Nrc Health · Insider Trading

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.

Represents restricted shares of common stock issued under the National Research Corporation 2025 Omnibus Incentive Plan. Subject to certain vesting, forfeiture, and termination provisions, the restricted shares vest in three equal installments on the following dates: (i) January 1, 2027, and (ii) January 1, 2028, and January 1, 2029.

The price in Column 4 is a weighted average price. The prices actually ranged from $12.01 to $12.33, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range set forth in this footnote.

This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings since the 2025 Annual Meeting of Stockholders.

This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings since the 2025 Annual Meeting of Stockholders.

Represents restricted shares of common stock issued under the National Research Corporation 2025 Omnibus Incentive Plan. Subject to certain vesting, forfeiture, and termination provisions, the restricted shares will vest in three approximately equal installments on the following dates: (i) January 5, 2027, (ii) January 5, 2028, and (iii) January 5, 2029.

This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.

This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.

This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.

Represents restricted shares of common stock issued under the National Research Corporation 2025 Omnibus Incentive Plan. Subject to certain vesting, forfeiture, and termination provisions, the restricted shares vest in four equal installments on the following dates: (i) December 28, 2025, (ii) September 29, 2026, (iii) September 29, 2027, and (iv) September 29, 2028.

Represents fully-vested shares of common stock issued under the National Research Corporation 2025 Omnibus Incentive Plan, which are subject to (i) certain transfer restrictions and (ii) repurchase by the issuer in certain circumstances.

The price reflects a weighted average purchase price for multiple transactions ranging from $13.555 to $13.6445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a stockholder of the issuer, full information regarding the number of shares purchased at each separate price.

This award is an annual grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan on the date of the Issuer's 2025 annual shareholder meeting. The award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to vesting, forfeiture, and termination provisions.

This award is an annual grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan on the date of the Issuer's 2025 annual shareholder meeting. The award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to vesting, forfeiture, and termination provisions.

This award is an annual grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan on the date of the Issuer's 2025 annual shareholder meeting. The award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to vesting, forfeiture, and termination provisions.

This award is an annual grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan on the date of the Issuer's 2025 annual shareholder meeting. The award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to vesting, forfeiture, and termination provisions.

This award is an annual grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan on the date of the Issuer's 2025 annual shareholder meeting. The award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to vesting, forfeiture, and termination provisions.

Represents fully-vested shares of common stock issued under the National Research Corporation 2006 Equity Incentive Plan, which are subject to (i) certain transfer restrictions and (ii) repurchase by the issuer in certain circumstances.

Represents fully-vested shares of common stock issued under the National Research Corporation 2006 Equity Incentive Plan, which are subject to (i) certain transfer restrictions and (ii) repurchase by the issuer in certain circumstances.

This option becomes fully exercisable on January 10, 2030.

On December 31, 2024, Amandla MK Trust was decanted to Common Property Trust. As a result, Common Property Trust became the sole owner of Amandla, LLC. The 4,755,317 shares held by Amandla, LLC as of December 31, 2024, reflects that 923,955 shares were transferred from Amandla II, LLC (then an indirect wholly owned subsidiary of Amandla MK Trust) to Amandla, LLC on April 5, 2024.

On December 31, 2024, Amandla MK Trust was decanted to Common Property Trust. As a result, Common Property Trust became the sole owner of Amandla, LLC.

This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.

This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.

This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.

This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.

This award is an annual grant to the reporting person made under the Issuer's 2004 Non-Employee Director Stock Plan (the "Plan") on the date of the Issuer's 2024 annual shareholder meeting. In accordance with the terms of the Plan, the award will vest and become exercisable on the date immediately preceding the date of the Issuer's next annual shareholder meeting, subject to certain exceptions provided in the Plan.

Represents a private sale of shares.

The price in Column 4 is a weighted average price. The prices actually ranged from $40.09 to $40.23, inclusive.

The price in Column 4 is a weighted average price. The prices actually ranged from $41.05 to $41.29, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the ranges set forth in footnotes (1) and (2) of this Form 4.

The price in Column 4 is a weighted average price. The prices actually ranged from $41.535 to $42.11, inclusive.

The price in Column 4 is a weighted average price. The prices actually ranged from $40.00 to $40.995, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the ranges set forth in footnotes (1), (2), and (3) of this Form 4.

The price in Column 4 is a weighted average price. The prices actually ranged from $41.00 to $41.335, inclusive.